<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915382</url>
  </required_header>
  <id_info>
    <org_study_id>AMC0902</org_study_id>
    <nct_id>NCT00915382</nct_id>
  </id_info>
  <brief_title>Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS</brief_title>
  <official_title>Phase III Trial of 3-weekly vs. 5-weekly Schedule of S-1 Plus Cisplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul Veterans Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The urgent need for a new effective therapy with better safety profile for the metastatic&#xD;
      gastric cancer patients and promising results observed so far in the studies with S-1 plus&#xD;
      cisplatin combination in advanced gastric cancer (AGC) strongly warrants the comparison of a&#xD;
      3-weekly schedule to a 5-weekly schedule of S-1 plus cisplatin as a standard regimen in the&#xD;
      first-line treatment for AGC patients.&#xD;
&#xD;
      The objectives of this study are to compare a 3-weekly schedule to a 5-weekly schedule of S-1&#xD;
      plus Cisplatin combination in terms of efficacy, quality of life and safety in patients with&#xD;
      previously untreated advanced or recurrent unresectable gastric cancer. Primary endpoint is&#xD;
      progression-free survival. This is an open label, randomized, multi-center,&#xD;
      non-inferiority/superiority (of 3-weekly regimen over 3-weekly regimen) hybrid study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of this study is Progression Free Survival (PFS). It is defined as the&#xD;
      time from the date of randomization to the time of disease progression as assessed by the&#xD;
      investigators, or death due to any cause. The primary goal of this study is to compare two&#xD;
      different schedules of S-1 plus cisplatin combination treatments (3-weekly regimen vs.&#xD;
      5-weekly regimen) for advanced gastric cancer with respect to the PFS based on the hybrid&#xD;
      design where we can test superiority and non-inferiority in the same trial (Reference:&#xD;
      Journal of Clinical Oncology 25: 5019-5023, 2007, Boris Freidlin, et el). First, the&#xD;
      non-inferiority hypothesis will be tested based on the non-inferiority margin 1.15. If the&#xD;
      inferiority cannot be rejected(meaning non-inferiority is proven) then the superiority will&#xD;
      be tested. If the superiority test is positive, then superiority is concluded; otherwise&#xD;
      non-inferiority without superiority will be concluded.&#xD;
&#xD;
      The sample size was calculated from the following consideration:&#xD;
&#xD;
      For non-inferiority test: non-inferiority margin 1.15, 10 percent reduction of hazard ratio,&#xD;
      power 80 percent, alpha 0.025, accrual period 36 months, follow-up period 12 months, and the&#xD;
      expected median PFS of 6 months for 5 weekly regimen were assumed. Based on the above&#xD;
      considerations, total of 560 patients will be need. With 10 percent follow-up loss, we need&#xD;
      622 patients.&#xD;
&#xD;
      For superiority test: the median PFS for 5-weekly regimen is expected to be 6 months and 7.5&#xD;
      months for 3-weekly regimen. With sample size of 560 patients calculated above, for detecting&#xD;
      1.5 months difference in the median PFS between the two groups , we will have 81 percent of&#xD;
      power, one-sided 5 percent type I error. Using the log rank test assuming exponential&#xD;
      underlying distribution, accrual period of 36 months, minimum of 12 months follow-up after&#xD;
      the last enrolment, 516 events will be needed to show the superiority of 3 week cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>accrual of patients for 36 months, followup of the last patient for 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>accrual of patients for 36 months, followup of the last patient for 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">625</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>3 weekly regimen of S-1 and cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5 weekly regimen of S-1 and cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 and cisplatin</intervention_name>
    <description>S-1: 80 mg/m2/day po on Days 1-14&#xD;
cisplatin: 60 mg/m2 iv on Day 1</description>
    <arm_group_label>3 weekly regimen of S-1 and cisplatin</arm_group_label>
    <other_name>TS-1 and cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 and cisplatin</intervention_name>
    <description>S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and&#xD;
cisplatin: 60 mg/m2 iv on Day 1 or 8</description>
    <arm_group_label>5 weekly regimen of S-1 and cisplatin</arm_group_label>
    <other_name>TS-1 and cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented metastatic or recurrent gastric adenocarcinoma including&#xD;
             adenocarcinoma of the gastro-esophageal junction&#xD;
&#xD;
          -  Age 18 to 74 years old&#xD;
&#xD;
          -  Performance status (ECOG scale) 0-2&#xD;
&#xD;
          -  No significant problems for oral intake and drug administration&#xD;
&#xD;
          -  At least one measurable or evaluable disease defined by RECIST&#xD;
&#xD;
          -  Adequate bone marrow function (ANC ≥ 1,500/uL, Platelet ≥ 100,000/ uL, Hb ≥ 9.0 g/dl)&#xD;
&#xD;
          -  Adequate renal function: serum creatinine ≤ UNL (if serum creatinine &gt; UNL, creatinine&#xD;
             clearance should be ≥ 60 mL/min)&#xD;
&#xD;
          -  Adequate hepatic function (Total bilirubin &lt; 2 x UNL and AST/ALT levels &lt; 3 x UNL&#xD;
             without liver metastasis,total bilirubin &lt; 3x ULN and AST/ALT levels &lt; 5 x UNL with&#xD;
             liver metastasis)&#xD;
&#xD;
          -  Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive&#xD;
             immunotherapy) is allowed if at least 6 months has elapsed between completion of&#xD;
             adjuvant/neoadjuvant therapy and enrolment into the study) and cisplatin was not used&#xD;
             before&#xD;
&#xD;
          -  Patients should sign a written informed consent before study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor type other than adenocarcinoma&#xD;
&#xD;
          -  Previously exposed to any fluropymidine within 6 months before the study&#xD;
&#xD;
          -  Previously exposed to Platinum therapy regardless of its period and/or duration&#xD;
&#xD;
          -  Microscopic residual disease only after noncurative gastrectomy with R1 resection&#xD;
             (resection margin positive)&#xD;
&#xD;
          -  Second primary malignancy (except in situ carcinoma of the cervix or adequately&#xD;
             treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years&#xD;
             ago without recurrence)&#xD;
&#xD;
          -  Prior radiotherapy was administered to target lesions selected for this study, or&#xD;
             radiotherapy to the non-target lesions has been completed within 4 weeks before&#xD;
             randomization&#xD;
&#xD;
          -  Presence of CNS metastasis&#xD;
&#xD;
          -  Major surgery within 4 weeks before initiation of study treatment or lack of complete&#xD;
             recovery from the effects of major surgery (patient received curative operation or RFA&#xD;
             for metastatic disease)&#xD;
&#xD;
          -  Serious illness or medical conditions:&#xD;
&#xD;
               -  Congestive heart failure (NYHA class III or IV)&#xD;
&#xD;
               -  Unstable angina or myocardial infarction within the past 12 months&#xD;
&#xD;
               -  Significant arrhythmias requiring medication and conduction abnormality such as&#xD;
                  over 2nd degree AV block&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Hepatic cirrhosis (≥ Child class B)&#xD;
&#xD;
               -  Interstitial pneumonia&#xD;
&#xD;
               -  Pulmonary adenomatosis&#xD;
&#xD;
               -  Psychiatric disorder that may interfere with protocol compliance&#xD;
&#xD;
               -  Unstable diabetes mellitus&#xD;
&#xD;
               -  Uncontrolled ascites or pleural effusion&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
          -  Receiving a concomitant treatment interacting with S-1 or cisplatin:&#xD;
&#xD;
               -  Flucytosine (a fluorinated pyrimidine antifungal agent)&#xD;
&#xD;
               -  Antivirals such as sorivudine, ramivudine, brivudine or other chemically related&#xD;
                  agents, warfarin, phenprocoumon, phenytoin, allopurinol&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Women of child bearing potential not using a contraceptive method&#xD;
&#xD;
          -  Sexually active fertile men not using effective birth control during medication of&#xD;
             study drug and up to 6 months after completion of study drug if their partners are&#xD;
             women of child-bearing potential&#xD;
&#xD;
          -  Any patients judged by the investigator to be unfit to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won Ki Kang, M.D.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Kwang Kim, M.D.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Iee Park, M.D.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Ho Baek, M.D.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan University Hospital, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang Hak Sohn, M.D.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University Pusan Paik Hospital, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eun Ki Song, M.D.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital, Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Bok Shin, M.D.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung Hyun Yang, M.D.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea Cancer Center Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyung Hee Lee, M.D.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeungnam University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae Young Zang, M.D.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ik-Joo Chung, M.D.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

